Unlock instant, AI-driven research and patent intelligence for your innovation.

CD20 antibody and its application in treating cancer

An antibody and CDR3 technology, applied in the field of biomedicine, can solve the problems of adverse reactions, restrictions on the long-term application of Rituximab, and a complete remission rate of only 10%, achieving the effect of enhancing anti-tumor activity

Active Publication Date: 2021-09-07
北京科跃中楷生物技术有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because the Rituximab molecule contains 30% mouse-derived sequences, after long-term medication, it is easy to cause human anti-mouse antibody immune response (HAMA) and produce serious adverse reactions
At the same time, the clinical response rate of Rituximab is only 50%, and the complete remission rate is only 10%
Therefore, the long-term clinical application of Rituximab is seriously restricted.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD20 antibody and its application in treating cancer
  • CD20 antibody and its application in treating cancer
  • CD20 antibody and its application in treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1. Anti-CD20 Antibody Preparation

[0035] BALB / C mice were immunized with NS / 0 transfected with human CD20. The cells were resuspended in PBS and mixed with complete Freund's adjuvant at a ratio of 1:1. The primary immunization method was intraperitoneal injection, and the immunization dose was 1X10 per mouse. 7 cells. Subsequent booster immunizations were followed by intraperitoneal injections with the same dose of unadjuvanted cells every 3 days. For the first three days of cell fusion, at 0.5X10 7 The cells were immunized by intravenous injection. After 3 days, the mice were sacrificed by cervical dislocation, and the spleen was removed to prepare a single-cell suspension in PBS. Splenocytes were washed 3 times with DMEM medium. The mouse myeloma cells SP2 / 0 in the logarithmic growth phase and the isolated mouse splenocytes were mixed at a ratio of 1:4 and washed twice with DMEM. Cell fusion was carried out by means of PEG fusion. Confluent cells were...

Embodiment 2

[0036] Example 2. Antibody Humanization

[0037] Take 5 × 10 hybridoma cells obtained in Example 1 7 Add 1ml Trizol, mix well and transfer to a 1.5mL centrifuge tube, let stand for 5 minutes at room temperature; add 0.2ml chloroform, shake for 15 seconds, stand for 2 minutes, centrifuge at 4°C, 12000g for 5 minutes, take the supernatant and transfer it to In a new 1.5ml centrifuge tube; add 0.5ml isopropanol, gently mix the liquid in the tube, stand at room temperature for 10 minutes, centrifuge at 12000g for 15 minutes at 4°C, discard the supernatant; add 1ml 75% ethanol, light Wash the precipitate lightly, centrifuge at 12000g at 4°C for 5 minutes, discard the supernatant, air dry the precipitate, add DEPC water to dissolve, and obtain total RNA. Take the total RNA, and then use a reverse transcription kit (PrimeScript RT Master Mix, purchased from Takara) to synthesize the first strand of cDNA; using cDNA as a template, use PCR to amplify the variable region of the antibod...

Embodiment 3

[0041] Example 3. Affinity of humanized CD20 antibody to human CD20

[0042] Referring to the instructions of the amino coupling kit and human anti-capture kit, the human antibody capture antibody (AHC) was immobilized on the surface of the S series sensor chip (Sereis S Sensor Chip CM5) by amino coupling. Equilibrate at room temperature for 20-30 min, and load the chip into the instrument. Dilute the antigen with equilibration buffer, dilute the antigen 10 nM starting dilution 5 concentration gradients, and set 2 zero concentrations (ie, equilibration buffer) and one repeat concentration (generally the lowest concentration repeat). The CD20 antibody h12H7-IgG1 was diluted to the experimental working concentration with equilibration buffer, and sealed at 2-8°C for later use. The antigen flow rate was set to 50 μL / min, and the binding time was set to 3 min. The flow rate of HBS-EP+ buffer was set to 50 μL / min, and the dissociation time was set to 10 min. Use 3MMgCl 2 As a r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a CD20 antibody and its application in treating cancer. The invention provides a new CD20 antibody, its preparation and application. Wherein said antibody can better bind human CD20 protein, induce strong CDC killing activity, and can enhance anti-tumor activity at the same time.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a CD20 antibody and its application in treating cancer. [0002] technical background [0003] Cellular lymphomas are solid tumors that occur in cells, and can be mainly divided into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is very common in hematological malignancies and poses an extremely serious threat to human life and health. The B lymphocyte antigen CD20 is a unique marker on the surface of human B lymphocytes, mainly composed of 297 amino acids. According to different phosphorylation levels, CD20 has a molecular weight of 33-37KD and belongs to non-glycosylated phosphoproteins. The CD20 molecule is a transmembrane protein with four transmembrane domains, and its N-terminus and C-terminus are both located inside the cytoplasm. The main antigenic epitope of CD20 molecule is located between the third and fourth transmembrane regions, which is a loop region com...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00A61P35/02A61P35/04
CPCA61K2039/505A61P35/00A61P35/02A61P35/04C07K16/2887C07K2317/24C07K2317/56C07K2317/565C07K2317/734C07K2317/92
Inventor 柳静刘欢戴伟利
Owner 北京科跃中楷生物技术有限公司